Press Releases2023-06-30T06:58:03-04:00

Press Releases

1601, 2024

Bexion Pharmaceuticals, Inc. Announces Poster Presentation at ASCO GI 2024

COVINGTON, Ky., Jan. 16, 2024 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced a Trials in Progress poster presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), being held January 18-20, 2024, in San Francisco, CA. Poster details are included below. Poster Details: Session [...]

501, 2024

Bexion Pharmaceuticals, Inc. to Present at Biotech Showcase 2024

Company now enrolling a Phase 1b/2 study in 1st Line mCRC and a PK/PD study in CIPN COVINGTON, Ky., January 5, 2024 /PRNewswire/ — Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will present at Biotech Showcase 2024 during the J.P. Morgan [...]

1210, 2023

Bexion Pharmaceuticals, Inc. to Participate in the 3rd Annual Needham Private Biotech Company Virtual 1×1 Forum

COVINGTON, Ky., Oct. 12, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum. The conference will be held virtually, from October 17-18, 2023. Scott Shively, CEO and [...]

1010, 2023

Bexion Pharmaceuticals, Inc. Appoints Dr. Catherine Pearce, DHSc, MBA, to Board of Directors

COVINGTON, Ky., Oct. 10, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced the appointment of Dr. Catherine Pearce, DHSc, MBA, to the Company's Board of Directors, effective October 1, 2023. Dr. Catherine Pearce, DHSc, MBA Dr. Pearce is a seasoned [...]

2509, 2023

Bexion Pharmaceuticals, Inc. to Participate in the 2023 Cantor Global Healthcare Conference

COVINGTON, Ky., Sept. 25, 2023 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will participate in the 2023 Cantor Global Healthcare Conference. The conference will be held in New York, NY, from September 26-28, 2023. Scott Shively, CEO and President of Bexion Pharmaceuticals, will [...]

2906, 2023

Bexion Pharmaceuticals, Inc. to Present at the ESMO World Congress on Gastrointestinal Cancer 2023

COVINGTON, Ky., June 29, 2023– Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a new generation of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), announced today that the Company will be represented at the ESMO World Congress on Gastrointestinal Cancer 2023 taking place on June 28 – July 1, 2023, in Barcelona, Spain. Presentation Details: Title: BXQ-350: [...]

Go to Top